Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs

An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, Sarepta’s Exondys and Covis’ Makena.